JP2022543669A5 - - Google Patents

Info

Publication number
JP2022543669A5
JP2022543669A5 JP2022507737A JP2022507737A JP2022543669A5 JP 2022543669 A5 JP2022543669 A5 JP 2022543669A5 JP 2022507737 A JP2022507737 A JP 2022507737A JP 2022507737 A JP2022507737 A JP 2022507737A JP 2022543669 A5 JP2022543669 A5 JP 2022543669A5
Authority
JP
Japan
Prior art keywords
antigen
binding molecule
domain
molecule according
target molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507737A
Other languages
English (en)
Japanese (ja)
Other versions
JP7682853B2 (ja
JP2022543669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045309 external-priority patent/WO2021026409A1/en
Publication of JP2022543669A publication Critical patent/JP2022543669A/ja
Publication of JP2022543669A5 publication Critical patent/JP2022543669A5/ja
Priority to JP2025080907A priority Critical patent/JP2025114807A/ja
Application granted granted Critical
Publication of JP7682853B2 publication Critical patent/JP7682853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507737A 2019-08-08 2020-08-07 新規抗原結合分子フォーマット Active JP7682853B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080907A JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962884496P 2019-08-08 2019-08-08
US62/884,496 2019-08-08
US202063050483P 2020-07-10 2020-07-10
US63/050,483 2020-07-10
PCT/US2020/045309 WO2021026409A1 (en) 2019-08-08 2020-08-07 Novel antigen binding molecule formats

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080907A Division JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Publications (3)

Publication Number Publication Date
JP2022543669A JP2022543669A (ja) 2022-10-13
JP2022543669A5 true JP2022543669A5 (https=) 2023-08-16
JP7682853B2 JP7682853B2 (ja) 2025-05-26

Family

ID=72179250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507737A Active JP7682853B2 (ja) 2019-08-08 2020-08-07 新規抗原結合分子フォーマット
JP2025080907A Pending JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080907A Pending JP2025114807A (ja) 2019-08-08 2025-05-14 新規抗原結合分子フォーマット

Country Status (12)

Country Link
US (8) US12215148B2 (https=)
EP (1) EP4010371A1 (https=)
JP (2) JP7682853B2 (https=)
KR (1) KR20220058546A (https=)
CN (3) CN114585651A (https=)
AU (1) AU2020327000A1 (https=)
BR (1) BR112022002067A2 (https=)
CA (1) CA3150168A1 (https=)
IL (1) IL290371A (https=)
MX (1) MX2022001682A (https=)
TW (1) TW202120556A (https=)
WO (1) WO2021026409A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788079A4 (en) 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
BR112022002067A2 (pt) * 2019-08-08 2022-06-14 Regeneron Pharma Formatos de molécula de ligação ao antígeno
WO2021146464A1 (en) * 2020-01-15 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Pericyte-sparing therapy
WO2021256647A1 (ko) * 2020-06-19 2021-12-23 숙명여자대학교산학협력단 Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체, 돌연변이체로부터 유래된 유도만능줄기세포와 중간엽줄기세포 및 이의 용도
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
AU2010254013A1 (en) 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9337942B2 (en) 2009-12-07 2016-05-10 Ntt Docomo, Inc. Propagation path estimation method and program and apparatus using the same
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2566892B1 (en) * 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
UY34542A (es) 2011-12-23 2013-07-31 Mersana Therapeutics Inc ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 四価二重特異性抗体
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CA3138083A1 (en) 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN207626880U (zh) 2017-05-19 2018-07-20 厦门汇成峰户外用品有限公司 一种导演椅
JP7438942B2 (ja) * 2017-10-30 2024-02-27 エフ. ホフマン-ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
MX2020004196A (es) * 2017-11-01 2020-11-09 Hoffmann La Roche Trifab-contorsbody.
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
BR112022002067A2 (pt) * 2019-08-08 2022-06-14 Regeneron Pharma Formatos de molécula de ligação ao antígeno

Similar Documents

Publication Publication Date Title
JP2022543669A5 (https=)
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
JP2025114807A5 (https=)
JP2021042257A5 (https=)
JP2017504578A5 (https=)
JP2020508655A5 (https=)
JP2024532485A5 (https=)
JP2021159081A5 (https=)
JP2014158485A5 (https=)
JP2023509212A5 (https=)
JP2022545647A5 (https=)
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
IL272103B1 (en) Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
JP2025512953A5 (https=)
JP2024500335A5 (https=)
JP2016529213A5 (https=)
JP2021529524A5 (https=)
JP2025505611A5 (https=)
JP2024531915A5 (https=)
JP2024546875A5 (https=)
RU2022105671A (ru) Новые форматы антигенсвязывающих молекул
NZ775540B2 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
NZ775540A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
RU2024123283A (ru) Бифункциональная молекула, образованная путем слияния антитела pd1 и интерлейкина 2
JP2024531346A5 (https=)